title: Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists.
abstract: Ambulatory 24-h esophageal pH monitoring was carried out in 54 patients with erosive/ulcerative reflux esophagitis before a 12- to 24-week treatment with either ranitidine, 150 to 300 mg twice daily, or famotidine, 20 to 40 mg twice daily. After this period, 21 patients continued to present endoscopic evidence of esophagitis. Patients who did not respond to the therapy showed a more severe pretreatment pattern of acid reflux than those who healed, with regard to both median percentage time of reflux (16.2% versus 11.0%, respectively, p less than 0.05) and median number of reflux episodes (88.0 versus 55.0; p less than 0.05). Ambulatory 24-h esophageal pH-metry is therefore to be recommended in all patients with acid reflux symptoms, even in those who already show endoscopic lesions of the esophageal mucosa, since this test is a valid prognostic indicator of response to treatment.
authors.affiliation: Gastrointestinal Unit, L. Sacco Hospital, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Bianchi Porro
authors.forename: F
authors.initials: F
authors.lastname: Pace
authors.forename: O
authors.initials: O
authors.lastname: Sangaletti
mesh_terms: D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000503:physiopathology; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005764:Gastroesophageal Reflux / Q000503:physiopathology*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011899:Ranitidine / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D006635:Histamine H2 Antagonists; D015738:Famotidine; D011899:Ranitidine